Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions. DRUG DEVELOPMENT PARTNERSHIP AND LICENSE AGREEMENT FOR CUDC-906 AND CUDC-908Partnership and License Agreement • May 10th, 2012 • Curis Inc • Biological products, (no disgnostic substances) • Massachusetts
Contract Type FiledMay 10th, 2012 Company Industry JurisdictionTHIS DRUG DEVELOPMENT PARTNERSHIP AND LICENSE AGREEMENT (the “Agreement”) is entered into as of February 24, 2012 (the “Effective Date”) by and between CURIS, INC., a corporation organized under the laws of the State of Delaware, USA, having its principal offices at 4 Maguire Road, Lexington, MA 02421, USA (“Curis”), and GUANGZHOU BEBETTER MEDICINE TECHNOLOGY CO, LTD., a company organized under the laws of the People’s Republic of China, having its principal offices at Room C209, Sector C, Guangzhou International Business Incubator, 3 Juquan Road, Guangzhou Science Park, Guangdong 510663, People’s Republic of China (“GBMT”).